Dafra Pharma introduces Parol®, a high quality paracetamol, produced according to the strictest European criteria.
Parol® is indicated for the treatment of mild to moderate pain and fever.
Parol® is very popular because it has fewer contraindications than other painkillers and enjoys a good public image.
Parol® is a very effective medication with a good benefit/risk ratio. The main precaution to take, valid for all patients, is not to exceed the maximum authorized dose (4g/day for adults or 60 mg/kg per day for children), in order not to reach concentrations that may eventually be dangerous for the liver.
This is also the reason why the recommended intervals between doses must be respected: in adults, it is necessary to wait 4 hours after taking 500 mg and 6 hours after taking one gram; in children, it is necessary to distribute the doses over the whole 24 hours, i.e., one dose every 6 hours of 10 mg/kg.
MODE OF ACTION OF PAROL
Parol® acts by inhibiting the synthesis of prostaglandins which are the mediators of fever and pain. Parol® is used for the symptomatic treatment of pain and fever. This means that Parol® relieves symptoms, but does not cure. Within half an hour of use, one may notice that pain and fever as well as aches and pains (such as headaches, sore throats, etc.) decrease. This effect lasts from three to six hours.
Parol® (paracetamol) is known for its good tolerance. In particular, it causes little or no irritation of the gastrointestinal tract. Its use is authorized during pregnancy and breastfeeding. The main precaution is to avoid overdosing, which is toxic for the liver.
Suspension available in: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Ivory Coast, Democratic Republic of the Congo, Gabon, Guinea, Kenya, Liberia, Mali, Mozambique, Niger, Rep. of Congo, Rwanda, Senegal, Somalia, Tchad & Togo
Tabs available in: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Ivory Coast, Democratic Republic of the Congo, Gabon, Guinea, Kenya, Liberia, Mali, Mauritania, Mozambique, Niger, Rep of Congo, Rwanda, Senegal, Somalia, Tchad & Togo
The active substance in Pedifen® is ibuprofen. The molecule belongs to the therapeutic class of non-steroidal anti-inflammatory drugs
Pedifen® has
analgesic properties (painkiller)
antipyretic properties (against fever)
anti-inflammatory properties
and also inhibits short term platelet functions
All these properties are linked to an inhibition of the synthesis of prostaglandins.
Suspension available in: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Ivory Coast, Democratic Republic of the Congo, Gabon, Guinea, Kenya, Liberia, Mali, Mauritania, Mozambique, Niger, Rep. of Congo, Rwanda, Senegal, Somalia, Tchad & Togo
Tabs available in: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Ivory Coast, Democratic Republic of the Congo, Gabon, Guinea, Kenya, Liberia, Mali, Mauritania, Mozambique, Niger, Rep of Congo, Rwanda, Senegal, Somalia, Tchad & Togo
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma